Taha Nazir

Dr. Taha Nazir

Microbiology & Molecular biology, Advanced Multiple Incorporation, Mississauga, Ontario, Canada
orcid
Microbiologist, Pharmacologist, Pharmacist

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in International Journal of Health Sciences (Qassim)
Verified
Journal Article
Open access
PDF file
Taha NazirTaha Nazir
Taha Nazir
SASuraj Abraham
Suraj Abraham
AIAzharul Islam
Azharul Islam
Tuberculosis | Multidrug Resistant | Class I Integron | NDM-1

1 January 2015 in Breast Disease
Verified
Journal Article
Closed access
PDF file
Taha NazirTaha Nazir
Taha Nazir
AIAzharul Islam
Azharul Islam
MOMuhammad Ovais Omer
Muhammad Ovais Omer
MMMazhar Mustafa
Mazhar Mustafa
Cancer chemotherapy exerts deleterious effects in patients, causing structural and physiological changes to their vital organs. These drugs are capable of destroying bone marrow cells and may reduce lymphocyte count. This study was aimed to investiga

1 October 2022
Verified
Journal Article
Closed access
RKRuqaiya Rasheed Kayani
Ruqaiya Rasheed Kayani
RSRahat Shamim
Rahat Shamim
SMSafia Sultana Munir
Safia Sultana Munir
MSMisbah Sultana
Misbah Sultana
SNSaeed Nazir
Saeed Nazir
AIAzharul Islam
Azharul Islam

1 January 2016 in Indian Journal of Pharmaceutical Education and Research
Verified
Journal Article
Open access
Taha NazirTaha Nazir
Taha Nazir
AIAzharul Islam
Azharul Islam
NTNida Taha
Nida Taha
SNSaeed Urasheed Nazir
Saeed Urasheed Nazir
MCMuhammad Ather Chaudhary
Muhammad Ather Chaudhary
MIMuhammad Iqbal
Muhammad Iqbal

11 May 2023 in Turkish Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
Taha NazirTaha Nazir
Taha Nazir
NTNida Taha
Nida Taha
AIAzharul Islam
Azharul Islam
IRIshtiaq Rabbi
Ishtiaq Rabbi
PSPervaiz Akhter Shah
Pervaiz Akhter Shah
The recently explained cytokine, which is produced after the stimulation of interferon (IFN)-c, interleukin (IL)-2, and IL-18 is IL-32, has pro-inflammatory IFN-c, IL-2 and IL-18 are IL-32 mediator’s properties that are generally entailed in many diseases, including infections, cancer, and chronic inflammation. After the initial statement in 2005, it promoted the osteoclast precursor’s differentiation into TRAcP plus VNR plus multinucleated cells that express explicit osteoclast indicators. Furthermore, the loss of bone resorption might be accredited because of the collapse of the multinucleated cells, which are produced of the reaction to IL-32 to direct factoring that is ultimately essential for attaching the cells for bone resorption. Thus, in conclusion, IL-32, the pro-inflammatory mediator, has an important and indirect role in regulating osteoclast differentiation. In bone disorder’s pathophysiology, critical role of IL-32 needs more scientific evidence to develop a rational treatment protocol. IL-32 can become a potent mediator of active osteoclast generation in the presence of receptor activator of NF-κB ligand (RANKL). This novel cytokine can introduce more favorable conditions for osteoclastogenesis in the rheumatic arthritis by increasing the RANKL and osteoprotegerin ratio in fibroblast-like synoviocytes.

1 January 2011 in Journal of Basic & Applied Sciences
Verified
Journal Article
Closed access
Taha NazirTaha Nazir
Taha Nazir